CD22 and acute lymphoblastic leukemia: In a large study (n = 58) of children and young adults receiving CD22-targeted/4-1BB CART cell therapy for relapsed/refractory CD22+ B-ALL (18), 86% developed any grade CRS [≥ Grade 3 in 10% per Lee (3) and 24% by ASTCT grading criteria (9)].